Metronomic 5-fluorouracil delivery primes skeletal muscle for myopathy but does not cause cachexia

9Citations
Citations of this article
8Readers
Mendeley users who have this article in their library.

Abstract

Skeletal myopathy encompasses both atrophy and dysfunction and is a prominent event in cancer and chemotherapy-induced cachexia. Here, we investigate the effects of a chemotherapeutic agent, 5-fluorouracil (5FU), on skeletal muscle mass and function, and whether small-molecule therapeutic candidate, BGP-15, could be protective against the chemotoxic challenge exerted by 5FU. Additionally, we explore the molecular signature of 5FU treatment. Male Balb/c mice received metronomic tri-weekly intraperitoneal delivery of 5FU (23 mg/kg), with and without BGP-15 (15 mg/kg), 6 times in total over a 15 day treatment period. We demonstrated that neither 5FU, nor 5FU combined with BGP-15, affected body composition indices, skeletal muscle mass or function. Adjuvant BGP-15 treatment did, however, prevent the 5FU-induced phosphorylation of p38 MAPK and p65 NF-κB subunit, signalling pathways involved in cell stress and inflammatory signalling, respectively. This as associated with mitoprotection. 5FU reduced the expression of the key cytoskeletal proteins, desmin and dystrophin, which was not prevented by BGP-15. Combined, these data show that metronomic delivery of 5FU does not elicit physiological consequences to skeletal muscle mass and function but is implicit in priming skeletal muscle with a molecular signature for myopathy. BGP-15 has modest protective efficacy against the molecular changes induced by 5FU.

References Powered by Scopus

Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

75829Citations
N/AReaders
Get full text

Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex

5673Citations
N/AReaders
Get full text

Dose translation from animal to human studies revisited

5146Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Chemotherapy-induced myopathy: The dark side of the cachexia sphere

40Citations
N/AReaders
Get full text

Chemotherapy-Induced Molecular Changes in Skeletal Muscle

15Citations
N/AReaders
Get full text

Obesity reduced survival with 5-fluorouracil and did not protect against chemotherapy-induced cachexia or immune cell cytotoxicity in mice

12Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Campelj, D. G., Timpani, C. A., Cree, T., Petersen, A. C., Hayes, A., Goodman, C. A., & Rybalka, E. (2021). Metronomic 5-fluorouracil delivery primes skeletal muscle for myopathy but does not cause cachexia. Pharmaceuticals, 14(5). https://doi.org/10.3390/ph14050478

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

100%

Readers' Discipline

Tooltip

Biochemistry, Genetics and Molecular Bi... 1

100%

Article Metrics

Tooltip
Mentions
Blog Mentions: 1

Save time finding and organizing research with Mendeley

Sign up for free